BioSpace News Archive

Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced that Chief Executive Officer Patrick Jordan will participate in a spotlight presentation at BIO-Europe 2019 being held November 11-13 in Hamburg, Germany.

The Jennifer Leigh Muma Neonatal Intensive Care Unit at Tampa General cares for about 100 babies a year who have been exposed to opiates or other substances.

Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has joined the Scientific & Medical Affairs Industry Membership of the Pancreatic Cancer Action Network (“PanCAN”), a worldwide leader in the fight against pancreatic cancer.

The Pancreatic Cancer Action Network (PanCAN) announced today the official launch of its Pancreatic Cancer Awareness Month campaign, running throughout the month of November.

The Company intends to release its financial results and to file its 10-Q after the close of the market on November 14, 2019 followed by the conference call.

The investment will accelerate commercial, engineering, and research and development activities in order to advance research-grade data insights for life science companies.

Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra

This collaboration will lay the groundwork for Optina’s future pivotal clinical trial.

Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on Thursday, November 14th, 2019.

A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the benefit of oral immunotherapy (OIT) for peanut allergy treatment and highlights the potential risks of allergy immunotherapy discontinuation.